143 related articles for article (PubMed ID: 32715381)
1. Investigation of Safety and Tolerability of ASP3652 Based on Clinical Studies of Cerebrospinal Fluid Transfer After Multiple Doses and Exposure After Single Doses at High Dose Levels.
Takizawa M; Cerneus D; Michon I; Rijnders S; Meijer J; Someya A; Sato Y
Adv Ther; 2020 Sep; 37(9):3967-3984. PubMed ID: 32715381
[TBL] [Abstract][Full Text] [Related]
2. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652 in First-in-Human and Ascending Multiple Oral Dose Studies in Healthy Subjects.
Takizawa M; Cerneus D; Michon I; Rijnders S; van der Heide D; Meijer J; Stoelzel M; Sato Y
Adv Ther; 2020 Sep; 37(9):3878-3900. PubMed ID: 32681461
[TBL] [Abstract][Full Text] [Related]
3. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
[TBL] [Abstract][Full Text] [Related]
5. Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies.
Fuertig R; Goettel M; Herich L; Hoefler J; Wiebe ST; Sharma V
CNS Drugs; 2023 Dec; 37(12):1081-1097. PubMed ID: 38019355
[TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
[TBL] [Abstract][Full Text] [Related]
7. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
8. Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers.
Pawsey S; Wood M; Browne H; Donaldson K; Christie M; Warrington S
Drugs R D; 2016 Jun; 16(2):181-91. PubMed ID: 26987975
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.
Paquette JM; Rufiange M; Iovu Niculita M; Massicotte J; Lefebvre M; Colin P; Telmat A; Ranger M
Clin Ther; 2014 Nov; 36(11):1650-64. PubMed ID: 25224876
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects.
Li GL; Winter H; Arends R; Jay GW; Le V; Young T; Huggins JP
Br J Clin Pharmacol; 2012 May; 73(5):706-16. PubMed ID: 22044402
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
Muirhead GJ; Osterloh IH; Whaley S; van den Berg F
J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects.
Han K; Cremer J; Elston R; Oliver S; Baptiste-Brown S; Chen S; Gardiner D; Davies M; Saunders J; Hamatake R; Losos J; Leivers M; Hood S; van der Berg F; Paff M; Ritter JM; Theodore D
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):790-801. PubMed ID: 30861337
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
Timmers M; Ravenstijn P; Xi L; Triana-Baltzer G; Furey M; Van Hemelryck S; Biewenga J; Ceusters M; Bhattacharya A; van den Boer M; van Nueten L; de Boer P
J Psychopharmacol; 2018 Dec; 32(12):1341-1350. PubMed ID: 30260294
[TBL] [Abstract][Full Text] [Related]
15. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
[TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Volunteers.
Rocha JF; Santos A; Gama H; Moser P; Falcão A; Pressman P; Wallace Hayes A; Soares-da-Silva P
Clin Pharmacol Ther; 2022 Feb; 111(2):391-403. PubMed ID: 33998672
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.
Shen Z; Gillen M; Miner JN; Bucci G; Wilson DM; Hall JW
Drug Des Devel Ther; 2017; 11():2077-2086. PubMed ID: 28744099
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies.
Desai A; Benner L; Wu R; Gertsik L; Uz T; Marek GJ; Zhu T
Clin Pharmacokinet; 2021 Jan; 60(1):79-88. PubMed ID: 32533536
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects.
Sun C; Liu H; Ouyang Z; Ding J; Zhang Q; Ma H; Xu D; Zhang Q; Zhou R; Yang M; Hu W
Expert Opin Investig Drugs; 2024 May; 33(5):533-542. PubMed ID: 38662639
[TBL] [Abstract][Full Text] [Related]
20. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
